ダパグリフロジンに対する反応としてエジェクション分数 (HFrEF) が減少した心不全患者の腎臓アウトカムに対する薬剤遺伝子の影響
PubMedで要約を見る
まとめ
この要約は機械生成です。ダパグリフロジンで治療された心不全患者のSLC5A2とUMODの遺伝的変異が腎機能に影響します. この薬学的洞察は,腎臓の改善のために治療を個別化することができます.
科学分野
- ファルマゲノミクス
- 心臓内科
- 心臓 不全 の 遺伝
背景
- 腎臓の合併症が多く,予後が悪化する.
- ダパグリフロジンのようなナトリウム・グルコース共輸送体-2 (SGLT2) 阻害剤は,HFrEFにおいて心肺血管に有益である.
- ダパグリフロジンに対する個々の反応は様々で,薬学的要因が関わっていることを示唆している.
研究 の 目的
- ダパグリフロジンを投与するHFrEF患者における遺伝的ポリモルフィズムが腎臓のアウトカムにどのように影響するかを調査する.
- SLC5A2,UMOD,KCNJ11,ACEを含む遺伝子の変異を分析する.
- HFrEFにおけるダパグリフロジン治療の最適化のための遺伝子マーカーを特定する.
主な方法
- エジプトのカイロで200人のHFrEF患者を対象とした前向きな観察コホート研究.
- TaqManTMアッセイを用いた単一ヌクレオチドポリモルフィズム (SNP) の遺伝子型決定
- ベースラインと6ヶ月の推定グルメルフィルタレーション率 (eGFR),KIM-1,NGAL値の評価
主要な成果
- 特定のSLC5A2 (rs3813008 AA遺伝子型) とUMOD (rs12917707 TT遺伝子型) 変異は,腎機能の改善と関連していました.
- rs3813008 AA遺伝子型の患者は,KIM-1とNGALの有意なEGFR増加と減少を示した.
- KCNJ11 (rs5219) ポリモルフィズムについては,腎臓のアウトカムに有意な影響は見られなかった.
結論
- 特にSLC5A2およびUMODにおける薬剤遺伝的変異は,HFrEFにおけるダパグリフロジンの腎臓効果に大きく影響する.
- これらの発見は,HFrEF治療の調整のためのパーソナライズド医療の可能性を裏付けています.
- HFrEF患者における腎臓のアウトカムを改善するために,遺伝的プロファイリングはダパグリフロジン治療を最適化することができます.
関連する概念動画
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...

